Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
The method covered by this patent expands
"This patent extends our coverage for capturing and analyzing rare cells of interest, including CTCs, and expands our international footprint, which is a strategic priority as we work to grow our business globally," said
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve patient outcomes, and the ability of our tests to provide clinically actionable information to oncologist and their patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Investor Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-receives-hong-kong-patent-covering-the-enhanced-detection-of-rare-cells-including-cancer-cells-301167780.html
SOURCE